1. In Vivo
  2. >>Outlook
  3. >>Outlook Archive

Clinical Trials: Have We Finally Reached The New Normal?

 
• By Heidi Chen

Pent-up trial demand during 2020 plus trial modernization strategies yields bumper performance in 2021 as research priorities revert to pre-pandemic trends.

Test tubes
• Source: Shutterstock

The COVID-19 pandemic brought acute disruption to the clinical trials landscape in 2020. While there was an explosion of trials initiated in infectious disease, clinical trials in other therapeutic areas endured setbacks in enrollment and progression. With the uptake of vaccinations from late 2020 through 2021, and the rollercoasters of variants that dashed hopes of returns to normalcy, the entire health care industry is learning to coexist with COVID-19. Clinical research, however, has adapted more quickly and early signals of recovery have translated into an impressive full-year performance in 2021. Exploring the trends within clinical trials that initiated during 2021, contrasting against pre- and peri-pandemic themes, reveals whether a post-pandemic, new normal has now been established.

According to the industry-leading clinical trial database Trialtrove, 2021 saw more than 10,000 Phase I–III clinical trials initiated for the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Outlook Archive

More from Outlook

Investor Optimism Ahead As Big Medtech Proves ‘It’s All About Value’

 
• By Ashley Yeo

Pressure to exploit connected care functionality is accelerating the shift in care delivery away from the inpatient setting. Medtechs are reshaping to maximize faster-growth opportunities.

2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy

 
• By Joseph Haas

Nine biopharma companies made 12 or more deals, with Novartis inking 21 deals and leading M&A activity. Roche, meanwhile, spent little up front but maintained a hectic pace with 12 alliances.

Big Pharma Headcounts: Obesity Leaders Bulk Up As Others Go Lean

 
• By Andrew McConaghie

As Eli Lilly and Novo Nordisk reap the blockbuster rewards of their rival obesity therapies the companies are also bulking up their organizations to make the most of the phenomenal rise of the GLP-1 class.